TLR7 agonism accelerates disease in a mouse model of primary Sjögren’s syndrome and drives expansion of T-bet+ B cells

• Published in: Frontiers in immunology Vol. 13; p. 1034336
• Main Authors: Punnanitinont, Achamaporn, Kasperek, Eileen M., Kiripolsky, Jeremy, Zhu, Chengsong, Miecznikowski, Jeffrey C., Kramer, Jill M.
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 15.12.2022
• Subjects: ABC; Adjuvants, Immunologic - pharmacology; age-associated B cells; Animals; autoantibodies; autoimmunity; B-Lymphocytes - drug effects; B-Lymphocytes - immunology; Female; Imiquimod - pharmacology; Immunology; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Myeloid Differentiation Factor 88 - genetics; Myeloid Differentiation Factor 88 - immunology; NOD.B10; sialadenitis; Sjogren's Syndrome - genetics; Sjogren's Syndrome - immunology; Toll-Like Receptor 7 - agonists; Toll-Like Receptor 7 - genetics; Toll-Like Receptor 7 - immunology; ABC; autoimmunity; sialadenitis; autoantibodies; age-associated B cells; NOD.B10
• DOI: 10.3389/fimmu.2022.1034336
• ISSN: 1664-3224

Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterized by chronic inflammation of exocrine tissue, resulting in loss of tears and saliva. Patients also experience many extra-glandular disease manifestations. Treatment for pSS is palliative, and there are currently no treatments available that target disease etiology. Previous studies in our lab demonstrated that MyD88 is crucial for pSS pathogenesis in the NOD.B10Sn- H2 b (NOD.B10) pSS mouse model, although the way in which MyD88-dependent pathways become activated in disease remains unknown. Based on its importance in other autoimmune diseases, we hypothesized that TLR7 activation accelerates pSS pathogenesis. We administered the TLR7 agonist Imiquimod (Imq) or sham treatment to pre-disease NOD.B10 females for 6 weeks. Parallel experiments were performed in age and sex-matched C57BL/10 controls. Imq-treated pSS animals exhibited cervical lymphadenopathy, splenomegaly, and expansion of TLR7-expressing B cells. Robust lymphocytic infiltration of exocrine tissues, kidney and lung was observed in pSS mice following treatment with Imq. TLR7 agonism also induced salivary hypofunction in pSS mice, which is a hallmark of disease. Anti-nuclear autoantibodies, including Ro (SSA) and La (SSB) were increased in pSS mice following Imq administration. Cervical lymph nodes from Imq-treated NOD.B10 animals demonstrated an increase in the percentage of activated/memory CD4+ T cells. Finally, T-bet + B cells were expanded in the spleens of Imq-treated pSS mice. Thus, activation of TLR7 accelerates local and systemic disease and promotes expansion of T-bet-expressing B cells in pSS.